Type 2 Diabetes Trial, Recruiting NCT06519942 Sponsor: University Hospital, Ghent Condition: Type 2 Diabetes
Back to Type 2 Diabetes

Type 2 Diabetes Trial, Recruiting

NCT06519942
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are between 40 and 70 years old
  • People with a body mass index (a measure of body weight relative to height) between 18.5 and 35
  • For people with type 2 diabetes specifically: those who have been clinically diagnosed with type 2 diabetes for more than 10 years

Who may not be able to join:

  • People whose nerve damage may be caused by something other than the condition being studied, such as vitamin B12 deficiency, heavy alcohol use, or previous chemotherapy treatment
  • People who have been largely immobile for more than 3 months at any point in their past, or for more than 4 weeks in the last 6 months
  • People with serious heart or lung conditions, or cystic fibrosis
  • People with a condition where the body does not produce enough sex hormones (confirm with trial site)
  • People with ongoing inflammatory conditions affecting the joints or intestines
  • People with chronic muscle diseases
  • People currently being treated for cancer
  • People with a diagnosed condition affecting nutrition, an eating disorder, or those who have had weight-loss surgery
  • People currently taking blood thinners, steroid medications, or hormone-blocking treatments
  • For people with type 2 diabetes specifically: those whose diabetes is not well managed, as measured by a blood sugar marker called HbA1c being above 9%
  • For healthy participants without diabetes: those with a fasting blood sugar level above 100 mg/dl, or an HbA1c reading above 5.7%

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 20 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Bruno Lapauw, University Hospital, Ghent

Phone: 0479922969

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
University Hospital, Ghent
Registry
ClinicalTrials.gov
Start date
12 December 2023
Est. completion
1 November 2025

Where this trial is recruiting

🇧🇪 Belgium

Primary endpoints

Differences in muscle fiber type composition in persons with type 2 diabetes with diabetic peripheral neuropathy compared to persons with type 2 diabetes without diabetic neuropathy and healthy controls.

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 20 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov